Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Aztreonam

FDA-approved product (injectable, injection), marketed as Azactam, Azactam In Plastic Container, Aztreonam and 1 more.

Registered studies
50+
Lab records
165
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Aztreonam
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Cystic fibrosis
  • Infection
  • Pneumonia
  • Pyelonephritis
  • Sepsis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Monobactams
FDA pharmacologic class
Monobactam Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DF01; FDA class Monobactam Antibacterial

Repurposing investigation

Aztreonam is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA18.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli97.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae31.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 4 of 4 lab records
  • K. pneumoniae: measured active in 34 of 161 lab records
Open Aztreonam in ChEMBL Registered studies below
Show the latest 150 of 165 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Aztreonam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation

    NCT07759453 · start 2026-10-01

    Registered record
    Registry ID
    NCT07759453
    Conditions
    Liver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization
    Interventions
    Ceftazidime - Avibactam ( CAZ-AVI); Meropenem-Vaborbactam; Imipenem+Relebactam; Cefiderocol; Aztreonam; Eravacycline; Aztreonam-Avibactam; Amoxi Clavulanate; Piperacillin + Tazobactam; Tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2029-09-30
    Enrolment
    168

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization
    InterventionCeftazidime - Avibactam ( CAZ-AVI); Meropenem-Vaborbactam; Imipenem+Relebactam; Cefiderocol +6 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care

    NCT07236944 · start 2025-12

    Registered record
    Registry ID
    NCT07236944
    Conditions
    Febrile Urinary Tract Infection
    Interventions
    Pivmecillinam; Standard of Care (Investigator Choice)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-12
    Completion
    2029-03
    Enrolment
    560

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Urinary Tract Infection
    InterventionPivmecillinam; Standard of Care (Investigator Choice)
    PhasePhase 4
    Registry statusRecruiting

  • Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.

    NCT07204522 · start 2025-09-22

    Registered record
    Registry ID
    NCT07204522
    Conditions
    Febrile Neutropenia
    Interventions
    Carbapenems; Anti-Gram-positive agent; Antifungal agent; Ceftazidime-avibactam + Aztreonam
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-09-22
    Completion
    2027-09-22
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia
    InterventionCarbapenems; Anti-Gram-positive agent; Antifungal agent; Ceftazidime-avibactam + Aztreonam
    PhaseNot recorded
    Registry statusRecruiting

  • A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

    NCT06462235 · start 2024-09-25

    Registered record
    Registry ID
    NCT06462235
    Conditions
    Gram-negative Bacterial Infection
    Interventions
    Part A: ATM-AVI Single Dose, Cohorts 1-4; Part B: Multiple-dose ATM-AVI, Cohorts 1-4
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-09-25
    Completion
    2027-04-25
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-negative Bacterial Infection
    InterventionPart A: ATM-AVI Single Dose, Cohorts 1-4; Part B: Multiple-dose ATM-AVI, Cohorts 1-4
    PhasePhase 2
    Registry statusRecruiting

  • Real-world Multicentre Study of AZtreonam-AVIbactam Treatment With Infections or Suspected Infections Caused by Multidrug-resistant Gram-negative Bacteria

    NCT07176247 · start 2024-01-01

    Registered record
    Registry ID
    NCT07176247
    Conditions
    Critical Care; Infection; Antibiotic Resistance; Infectious Diseases
    Interventions
    Aztreonam-Avibactam
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Enrolling by invitation
    Start
    2024-01-01
    Completion
    2028-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Care; Infection; Antibiotic Resistance; Infectious Diseases
    InterventionAztreonam-Avibactam
    PhaseNot recorded
    Registry statusEnrolling by invitation

  • Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

    NCT05639647 · start 2023-04-18

    Registered record
    Registry ID
    NCT05639647
    Conditions
    Gram-negative Bacterial Infections
    Interventions
    ATM-AVI; BAT
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-04-18
    Completion
    2027-03-31
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-negative Bacterial Infections
    InterventionATM-AVI; BAT
    PhasePhase 2
    Registry statusRecruiting

  • Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies

    NCT05850871 · start 2023-01-06

    Registered record
    Registry ID
    NCT05850871
    Conditions
    Carbapenem-Resistant Enterobacteriaceae Infection
    Interventions
    CAZ/AVI plus Aztreonam; Conventional treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-01-06
    Completion
    2025-01-31
    Enrolment
    427

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-Resistant Enterobacteriaceae Infection
    InterventionCAZ/AVI plus Aztreonam; Conventional treatment
    PhaseNot applicable
    Registry statusUnknown

  • Pharmacokinetics of Meropenem and Aztreonam After Intraperitoneal Administration Via Cycler-therapy in APD Patients Without Peritonitis

    NCT07113574 · start 2021-08-31

    Registered record
    Registry ID
    NCT07113574
    Conditions
    Peritoneal Dialysis Associated Peritonitis; Peritoneal Dialysis (PD); Peritoneal Dialysis; Peritoneal Dialysis, Continuous Ambulatory; Meropenem; Aztreonam; Antibacterial Agents; Intraperitoneal Antibiotics; Kidney Failure, Chronic; Anti-Bacterial Agents; Drug Therapy
    Interventions
    Meropenem 1000 mg; Aztreonam 2000 mg; automated peritoneal dialysis with following long time dwell; Sampling
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-08-31
    Completion
    2022-07-24
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeritoneal Dialysis Associated Peritonitis; Peritoneal Dialysis (PD); Peritoneal Dialysis; Peritoneal Dialysis, Continuous Ambulatory +7 more
    InterventionMeropenem 1000 mg; Aztreonam 2000 mg; automated peritoneal dialysis with following long time dwell; Sampling
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study to Assess the Pharmacokinetics, Safety and Tolerability of Aztreonam-Avibactam in Healthy Chinese Participants.

    NCT04973826 · start 2021-08-20

    Registered record
    Registry ID
    NCT04973826
    Conditions
    Healthy
    Interventions
    Aztreonam-Avibactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-08-20
    Completion
    2021-09-27
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAztreonam-Avibactam
    PhasePhase 1
    Registry statusCompleted

  • Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

    NCT03580044 · start 2020-12-25

    Registered record
    Registry ID
    NCT03580044
    Conditions
    Serious Bacterial Infection
    Interventions
    ATM-AVI; BAT
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2020-12-25
    Completion
    2023-01-23
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSerious Bacterial Infection
    InterventionATM-AVI; BAT
    PhasePhase 3
    Registry statusTerminated

  • Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

    NCT03696290 · start 2019-10-19

    Registered record
    Registry ID
    NCT03696290
    Conditions
    Bronchiectasis Adult
    Interventions
    Aztreonam lysine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2019-10-19
    Completion
    2025-03-04
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchiectasis Adult
    InterventionAztreonam lysine; Placebo
    PhasePhase 4
    Registry statusTerminated

  • A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

    NCT03978091 · start 2019-07-09

    Registered record
    Registry ID
    NCT03978091
    Conditions
    Bacterial Infection
    Interventions
    AZACTAM; Ceftazidime-Avibactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-07-09
    Completion
    2020-11-23
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infection
    InterventionAZACTAM; Ceftazidime-Avibactam
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Aztreonam for Pharyngeal Gonorrhea

    NCT03867734 · start 2019-04-05

    Registered record
    Registry ID
    NCT03867734
    Conditions
    Gonorrhea of Pharynx; Gonorrhea
    Interventions
    Aztreonam
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2019-04-05
    Completion
    2019-09-30
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGonorrhea of Pharynx; Gonorrhea
    InterventionAztreonam
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Nebulized Aztreonam for Prevention of Gram Negative Ventilator-associated Pneumonia

    NCT03749226 · start 2019-03-19

    Registered record
    Registry ID
    NCT03749226
    Conditions
    Ventilator Associated Pneumonia; Prevention; Respiratory Infection Other
    Interventions
    Aztreonam lysine; Aerogen Solo; CombiHaler
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2019-03-19
    Completion
    2019-12-31
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia; Prevention; Respiratory Infection Other
    InterventionAztreonam lysine; Aerogen Solo; CombiHaler
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

    NCT03138733 · start 2018-08-26

    Registered record
    Registry ID
    NCT03138733
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Ceftobiprole medocaril; Daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-08-26
    Completion
    2022-03-11
    Enrolment
    390

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionCeftobiprole medocaril; Daptomycin
    PhasePhase 3
    Registry statusCompleted